TERN Terns Pharma: Total Company Value-to-Revenue Ratio

Public company logo of ternspharma.com (TERN)

Terns Pharmaceuticals relies on R&D outsourcing to minimize costs through external contractors. The EV/Revenue multiple reflects the dynamics of this model, and the current value of this indicator is 0.00. Valuation growth is supported by a staff of hepatology experts and the creation of an ecosystem of oral obesity drugs, the success of which depends on FDA safety requirements.

Terns Pharma - TERN Enterprise Value-to-Revenue Ratio (period 11/23/2025 - 05/16/2026)

Terns Pharma - analytical breakdowns and key metrics (TERN)

- share price and consensus valuation forecast:
Initial company analysis:ternspharma.com TERN
Product sample of Terns Pharmaceuticals, Inc.

Experienced management at Terns Pharmaceuticals (TERN), hailing from Big Pharma, ensures high transparency in clinical trials. This influences market expectations, which are reflected in the EV-to-total-revenue multiple. This metric compares the total enterprise value, including debt minus cash, with actual sales volume. It allows for an assessment of the premium paid for the asset regardless of financial leverage. Analyzing this chart helps identify company overvaluation in a timely manner.